The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

U.S. House Panel Spotlights Use of FDA Rules to Slow Generic Drugs

July 28, 2017 • By Diane Bartz

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—Republican and Democratic lawmakers on Thursday discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines.

You Might Also Like
  • Sun Pharma Gets U.S. Subpoena over Generic Drugs Pricing
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • U.S. Could File Charges in Generic Drug Probe by Year-End

The focus at a hearing, held by members of the House Judiciary Committee’s antitrust subcommittee, was on the use by some brand name drug companies of a U.S. Food and Drug Administration (FDA) program, called Risk Evaluation and Mitigation Strategies (REMS), to protect their pharmaceuticals from generic competition.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Under the FDA program, generic companies often must buy samples of a drug they want to copy from the brand name company that makes the drug, rather than a wholesaler.

Drugmakers have been accused of refusing to make such sales, and the House and Senate are both considering legislation that would allow generic drug companies to sue to demand samples.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The legislation under consideration would also provide for damages for generic companies denied access to brand name drugs.

Lawmakers from both parties expressed discomfort with the practice of blocking cheaper drugs from getting to market. Rep. John Conyers (D-Mich.), the Judiciary Committee’s top Democrat, asked how he could help to stop it.

High and rising drug prices have proved a pain point for many voters, particularly those without insurance or on tight budgets. Drug companies argue that they need the high prices to fund multibillion-dollar research to discover the next life-saving medicine.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Rep. Bob Goodlatte (R-Va.), the Judiciary Committee’s chairman, noted voter concerns about the high price of some medicines.

“While it is imperative that the U.S. continue to remain the world leader and innovator in the pharmaceutical market, it is important that … antitrust concerns be given significant deliberation,” he said.

Scott Gottlieb, an FDA commissioner, testified that drug companies sometimes “game” the government system.

Markus Meier, acting head of competition for the Federal Trade Commission, said any delay in the rollout of generic drugs has clear consequences.

“When drug companies can succeed in delaying generic entry, American consumers will pay higher prices for prescription drugs,” he said.

Under the FDA’s REMS program, 71 drugs are covered by varying levels of protection. In some of the most strict cases, the drugs can only be given to a patient on a registry or dispensed in a particular healthcare setting, like a clinic.

Drugs with REMS include Indivior’s Suboxone (buprenorphine/naloxone), Sanofi Genzyme’s Lemtrada (alemtuzumab) and Danco Laboratories’ Mifeprex (mifepristone).

Filed Under: Drug Updates Tagged With: FDA, Food and Drug Administration, generic drugmakers, generic drugs, generic pharmaceutical companies, REMS, Risk Evaluation and Mitigation Strategy, U.S. Food and Drug Administration

You Might Also Like:
  • Sun Pharma Gets U.S. Subpoena over Generic Drugs Pricing
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • U.S. Could File Charges in Generic Drug Probe by Year-End
  • Cephalon, U.S. States Reach $125 Million Settlement Over Generic Drugs

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)